Log in

Relevant bibliographies by topics / Patient Centric Agent / Journal articles

To see the other types of publications on this topic, follow the link: Patient Centric Agent.

Journal articles on the topic 'Patient Centric Agent'

Author: Grafiati

Published: 19 February 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Patient Centric Agent.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Uddin, Md Ashraf, Andrew Stranieri, Iqbal Gondal, and Venki Balasubramanian. "Continuous Patient Monitoring With a Patient Centric Agent: A Block Architecture." IEEE Access 6 (2018): 32700–32726. http://dx.doi.org/10.1109/access.2018.2846779.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Devadas, Rajeev Samuel. "Holochain-Based Electronic Health Records: A Segregated and Secure Approach." European Journal of Computer Science and Information Technology 13, no. 48 (2025): 126–41. https://doi.org/10.37745/ejcsit.2013/vol13n48126141.

Full text

Abstract:

The management of electronic health records (EHRs) faces persistent challenges related to security vulnerabilities, interoperability limitations, and inadequate patient control. This paper explores Holochain as a transformative architecture for health information systems that addresses these issues through a distributed agent-centric approach. Unlike centralized EHR systems that create single points of failure or conventional blockchain implementations with scalability constraints, Holochain enables each participant to maintain their own immutable record chain while participating in a larger d

APA, Harvard, Vancouver, ISO, and other styles

3

Rodriguez Almaraz, E., B. Miao, Y. Yadav, et al. "P10.06.A AGENT-BASED MODELING FOR PATIENT-CENTERED CLINICAL DECISION SUPPORT IN NEURO-ONCOLOGY." Neuro-Oncology 26, Supplement_5 (2024): v56. http://dx.doi.org/10.1093/neuonc/noae144.182.

Full text

Abstract:

Abstract BACKGROUND Complex clinical decision-making in neuro-oncology is a multifaceted process involving numerous specialties influenced by various objective factors and patient preferences. Modeling these multidisciplinary neuro-oncology discussions presents significant challenges, particularly given the multimodal nature of the data. Recent advancements in large language models (LLMs) have enabled the development of LLM “agents”. These agents pave the way for multi-agent systems capable of simulating interacting components, thus capturing the nuances of interdisciplinary clinical discussio

APA, Harvard, Vancouver, ISO, and other styles

4

Munavalli, Jyoti R., Shyam Vasudeva Rao, Aravind Srinivasan, and GG van Merode. "Integral patient scheduling in outpatient clinics under demand uncertainty to minimize patient waiting times." Health Informatics Journal 26, no. 1 (2019): 435–48. http://dx.doi.org/10.1177/1460458219832044.

Full text

Abstract:

This study addressed the problem of scheduling walk-in patients in real time. Outpatient clinics encounter uncertainty in patient demand. In addition, the disparate departments are locally (department-centric) organized, leading to prolonged waiting times for patients. The proposed integral patient scheduling model incorporates the status and information of all departments in the outpatient clinic along with all possible pathways to direct patients, on their arrival, to the optimal path. The developed hybrid ant agent algorithm identifies the optimal path to reduce the patient waiting time and

APA, Harvard, Vancouver, ISO, and other styles

5

Kostick-Quenet, Kristin M., Compagnucci Marcelo Corrales, Mateo Aboy, and Timo Minssen. "Patient-centric federated learning: automating meaningful consent to health data sharing with smart contracts." Journal of Law and the Biosciences 12, no. 1 (2025): lsaf003. https://doi.org/10.1093/jlb/lsaf003.

Full text

Abstract:

ABSTRACT: Federated Learning (FL) promises to enhance data-driven health research by enabling collaborative machine learning across distributed datasets without direct data exchange. However, current FL implementations primarily reflect the data-sharing interests of institutional controllers rather than those of individual patients whose data are at stake. Existing consent mechanisms—like broad consent under HIPAA or explicit consent under the GDPR—fail to provide patients with control over how their data is used. This article explores the integration of smart contracts (SCs) into

APA, Harvard, Vancouver, ISO, and other styles

6

Chee, Ying Jie, and Rinkoo Dalan. "Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future." Biomedicines 12, no. 7 (2024): 1386. http://dx.doi.org/10.3390/biomedicines12071386.

Full text

Abstract:

Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to rise. A substantial increase in the burden of CVD and renal disease, alongside the socioeconomic implications, would be anticipated. Adopting a purely glucose-centric approach focusing only on glycemic targets is no longer adequate to mitigate the cardiovascular risks in T2DM. In the past decade, significant advancement has been achieved in expanding the pharmaceutical options for T2DM, with novel agents such as the sodi

APA, Harvard, Vancouver, ISO, and other styles

7

Gupta, Mehul, Igor Stukalin, Daniel Meyers, et al. "Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma." JAMA Network Open 6, no. 6 (2023): e2319607. http://dx.doi.org/10.1001/jamanetworkopen.2023.19607.

Full text

Abstract:

ImportanceTreatment-free survival (TFS) represents an alternative time-to-event end point, accurately characterizing time spent free of systemic therapy, providing a more patient-centric view of immune checkpoint inhibitor (ICI) therapy regimens. There remains a lack of studies evaluating TFS outcomes among patients with advanced melanoma who are receiving immunotherapy, especially outside of the clinical trial setting.ObjectiveTo evaluate TFS outcomes for patients with advanced melanoma receiving first-line ICI therapy outside of a clinical trial setting.Design, Setting, and ParticipantsThis

APA, Harvard, Vancouver, ISO, and other styles

8

Calvaresi, Davide, and Jean-Paul Calbimonte. "Real-Time Compliant Stream Processing Agents for Physical Rehabilitation." Sensors 20, no. 3 (2020): 746. http://dx.doi.org/10.3390/s20030746.

Full text

Abstract:

Digital rehabilitation is a novel concept that integrates state-of-the-art technologies for motion sensing and monitoring, with personalized patient-centric methodologies emerging from the field of physiotherapy. Thanks to the advances in wearable and portable sensing technologies, it is possible to provide patients with accurate monitoring devices, which simplifies the tracking of performance and effectiveness of physical exercises and treatments. Employing these approaches in everyday practice has enormous potential. Besides facilitating and improving the quality of care provided by physioth

APA, Harvard, Vancouver, ISO, and other styles

9

Loaiza-Bonilla, Arturo, Selin Kurnaz, Ertugrul Tuysuz, Oz Huner, Dersu Giritlioglu, and Juan Pablo Noel Meza. "Transforming oncology clinical trial matching through multi-agent AI and an oncology-specific knowledge graph: A prospective evaluation in 3,800 patients." Journal of Clinical Oncology 43, no. 16_suppl (2025): 1554. https://doi.org/10.1200/jco.2025.43.16_suppl.1554.

Full text

Abstract:

1554 Background: Clinical trial enrollment in oncology is often hampered by the manual, time-intensive process of matching patients to trials with highly specific eligibility criteria. Advances in artificial intelligence (AI)—particularly multi-agent large language models (LLMs) and oncology-specific knowledge networks—hold promise for streamlining this workflow and minimizing human labor. This abstract presents a prospective evaluation of an AI platform that automates medical data extraction, leverages an oncology-specific knowledge graph, and provides real-time trial recommendations, demonst

APA, Harvard, Vancouver, ISO, and other styles

10

Simon, Samantha J., Rushad Patell, Jeffrey I. Zwicker, Dhruv S. Kazi, and Brian L. Hollenbeck. "Venous Thromboembolism in Total Hip and Total Knee Arthroplasty." JAMA Network Open 6, no. 12 (2023): e2345883. http://dx.doi.org/10.1001/jamanetworkopen.2023.45883.

Full text

Abstract:

ImportanceThe optimal pharmacologic thromboprophylaxis agent after total hip and total knee arthroplasty is uncertain and consensus is lacking. Quantifying the risk of postoperative venous thromboembolism (VTE) and bleeding and evaluating comparative effectiveness and safety of the thromboprophylaxis strategies can inform care.ObjectiveTo quantify risk factors for postoperative VTE and bleeding and compare patient outcomes among pharmacological thromboprophylaxis agents used after total hip and knee arthroplasty.Design, Setting, and ParticipantsThis retrospective cohort study used data from a

APA, Harvard, Vancouver, ISO, and other styles

11

Dotan, Efrat, Tianyu Li, Michael J. Hall, Neal J. Meropol, Robert J. Beck, and Yu-Ning Wong. "De-adoption of epidermal growth factor receptor (EGFR) inhibitors following recommendations for KRAS testing to guide treatment of metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 30, no. 34_suppl (2012): 191. http://dx.doi.org/10.1200/jco.2012.30.34_suppl.191.

Full text

Abstract:

191 Background: KRAS mutation status is a predictive biomarker for resistance to EGFR antibodies among mCRC pts, and is recommended for use by ASCO and the FDA. Little is known about the uptake of clinical recommendations in oncology practice. We sought to study the effect of ASCO and FDA guidelines on the use of EGFR antibodies among a commercially insured population. Methods: The LifeLink Health Plan Claims Database (formerly the PharMetrics Patient-Centric Database) was used to create a cohort of >18 yo mCRC pts treated between 2004-2010. We identified treatment and diagnosis using ICD-9

APA, Harvard, Vancouver, ISO, and other styles

12

Dotan, Efrat, Tianyu Li, Michael J. Hall, Neal J. Meropol, Robert J. Beck, and Yu-Ning Wong. "De-adoption of epidermal growth factor receptor (EGFR) inhibitors following recommendations for KRAS testing to guide treatment of metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14021-e14021. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14021.

Full text

Abstract:

e14021 Background: KRAS mutation status is a predictive biomarker for resistance to EGFR antibodies among mCRC pts, and is recommended for use by ASCO and the FDA. Little is known about the uptake of clinical recommendations in oncology practice. We sought to study the effect of ASCO and FDA guidelines on the use of EGFR antibodies among a commercially insured population. Methods: The LifeLink Health Plan Claims Database (formerly the PharMetrics Patient-Centric Database) was used to create a cohort of >18 yo mCRC pts treated between 2004-2010. We identified treatment and diagnosis using IC

APA, Harvard, Vancouver, ISO, and other styles

13

Chinda, Monika, Kiran Godse, T. S. Vidya, et al. "A real-world observational study to evaluate the safety & effectiveness of Naftifine 2% cream in patients with superficial fungal skin infection." IP Indian Journal of Clinical and Experimental Dermatology 10, no. 3 (2024): 260–65. http://dx.doi.org/10.18231/j.ijced.2024.046.

Full text

Abstract:

Naftifine hydrochloride, an allylamine, is a topical agent used in treating superficial fungal infections, especially dermatophytosis. The objective of this study was to assess the safety and effectiveness of naftifine 2% cream in Indian patients with superficial fungal skin infection. A real-world observational study to evaluate the safety & effectiveness of Naftifine 2% cream in patients with superficial fungal skin infection.It was an open-label, multi-centric, observational, prospective real-world study conducted on Indian patients, where subjects were advised to apply naftifine 2% cre

APA, Harvard, Vancouver, ISO, and other styles

14

Levi, Jelena, Timothy Perk, Lyna Huynh, et al. "45 AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A52. http://dx.doi.org/10.1136/jitc-2021-sitc2021.045.

Full text

Abstract:

BackgroundPatterns of response to immunotherapy differ from traditional cytotoxic drugs, making clinical decisions concerning response evaluation more challenging. Radiological response criteria, such as iRECIST, updated to address response patterns unique to immunotherapeutics, focus only on changes in the tumor burden.1 An 18F labeled nucleoside analog, [18F]F-AraG was developed as a PET agent for imaging activated T cells,2–5 critical components of immune response and the common target of immunotherapies. Whole body assessment of [18F]F-AraG uptake that indicates presence of activated T cel

APA, Harvard, Vancouver, ISO, and other styles

15

Feinberg, Bruce A., Richard Sweat, Yolaine Jeune-Smith, and Ajeet Gajra. "Potential of 2018 ASH CLL Data to Alter Standard of Care for Initial CLL Treatment." Blood 134, Supplement_1 (2019): 5816. http://dx.doi.org/10.1182/blood-2019-129029.

Full text

Abstract:

Introduction In the past 5 years, four drugs have received approval for the treatment of Chronic lymphocytic leukemia (CLL), with most of the data supporting their approvals presented at an ASH meeting. How treating hematologists and oncologists (H/O) incorporate these agents into their practice has implications for all stakeholders. We conducted market research with H/O to understand how CLL data presented at ASH 2018 might alter their treatment preferences. Methods A live meeting in February 2019 convened H/O. The participants were shown data from selected oral and/or poster presentations fr

APA, Harvard, Vancouver, ISO, and other styles

16

Stintzing, Sebastian, Isabel Virchow, Harald Mueller-Huesmann, et al. "Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC." Journal of Clinical Oncology 42, no. 16_suppl (2024): 3551. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3551.

Full text

Abstract:

3551 Background: Targeted treatment with encorafenib plus cetuximab (E+C) represents the standard of care for patients with BRAF V600E-mutant metastatic colorectal cancer after prior systemic therapy. The approval was based on the data from the BEACON CRC trial; updated data of the trial showed a median progression free survival (mPFS) of 4.3 months and a median overall survival (mOS) of 9.3 months for the treatment with E+C compared to a mPFS of 1.5 months and a mOS of 5.9 months with chemotherapy plus cetuximab (hazard ratio [HR], 0.61 [95% CI, 0.48 to 0.77]) and an objective response rate (

APA, Harvard, Vancouver, ISO, and other styles

17

E. Chavan, Santosh, Gaurav Shrivastava, Richa Girishchandra Gupta, and Patel Muktiben Rajendra. "Efficacy of Virechana Karma by Patolmooladi Kashayam: A Pilot Study." Journal of Neonatal Surgery 14, no. 32S (2025): 776–87. https://doi.org/10.63682/jns.v14i32s.7453.

Full text

Abstract:

Background: Ayurvedic classical texts emphasize that cleansing therapies (Shodhana) are vital for eradicating chronic disorders from the root, especially in skin diseases (Kushtha) which often involve vitiated Pitta and Rakta (blood). Virechana (therapeutic purgation) is regarded as the treatment of choice for Pitta-dominant conditions and can expel accumulated Doshas through the lower gastrointestinal tract. Patolamooladi Kashayam is an herbal decoction traditionally indicated in Kushtha Roga (Skin disorders, including various types of Kushtha and Shwitra (Vitiligo), Grahani (IBS), Arsha (Pil

APA, Harvard, Vancouver, ISO, and other styles

18

Lassau, Nathalie, Serge Koscielny, Sophie Taieb, et al. "Validation of imaging biomarker in a multicentric study to predict PFS in mRCC treated with TKI." Journal of Clinical Oncology 32, no. 4_suppl (2014): 526. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.526.

Full text

Abstract:

526 Background: Tyrosine kinase inhibitors including sunitinib are the most effective treatments of metastatic renal cell carcinoma (mRCC). A multi-centric study of 539 patients (different tumors treated anti-angiogenic treatments) evaluating dynamic contrast-enhanced ultrasound (DCE-US), showed that a decrease of AUC (Area under the curve) correlated to the blood volume at one month is predictive of response. Our first objective was to validate the correlation between this parameter and the PFS in a sub-group of mRCC treated with Sunitinib The second objective was to study the variability of

APA, Harvard, Vancouver, ISO, and other styles

19

Cabel, Luc, Delphine Loirat, Jerome Martin Babau, et al. "TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer." Journal of Clinical Oncology 42, no. 16_suppl (2024): TPS1142. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.tps1142.

Full text

Abstract:

TPS1142 Background: Sacituzumab govitecan (SG) is an anti-TROP2 antibody-drug conjugate (ADC) with an SN-38 payload (topoisomerase I inhibitor) that was recently approved for use in advanced triple-negative breast cancer (TNBC). The rapid spontaneous linker hydrolysis in sacituzumab-govitecan releases a very large amount of SN-38 cargo systemically, which may in part contribute to efficacy and also in part be responsible for systemic side effects (1). PLX038 is a 40 kDa 4-arm PEG-SN38 conjugate with a half-life of 5 days. It has a controlled, slow-release rate which allows high SN-38 exposure

APA, Harvard, Vancouver, ISO, and other styles

20

Liao, Yen-Tzu, Zhi-Kai Yu, Ching-Te Kuo, Wen-Ming Hsu, Yi-Xun Huang, and Hsinyu Lee. "Abstract 947: A nanodroplet cell processing platform for identifying synergistic drug combinations for neuroblastoma treatment in TH-MYCN transgenic mice." Cancer Research 84, no. 6_Supplement (2024): 947. http://dx.doi.org/10.1158/1538-7445.am2024-947.

Full text

Abstract:

Abstract Neuroblastoma is the most common pediatric extracranial solid tumor and contributes to more than 15% of child mortality. It is characterized by extreme heterogeneity and high-risk tumors often resulting in poor prognosis. Currently, chemotherapy is a prevailing standard treatment for neuroblastoma. However, it is plagued by multiple challenges such as drug resistance and debilitating side effects. Synergistic drug combination is proposed as an innovative approach to potentially improve clinical outcomes of single-agent chemotherapy. We propose a novel approach to screen for effective

APA, Harvard, Vancouver, ISO, and other styles

21

Apel-Sarid, Liat, Doug D. Cochrane, Paul Steinbok, Angela T. Byrne, and Christopher Dunham. "Microfibrillar collagen hemostat–induced necrotizing granulomatous inflammation developing after craniotomy: a pediatric case series." Journal of Neurosurgery: Pediatrics 6, no. 4 (2010): 385–92. http://dx.doi.org/10.3171/2010.8.peds10248.

Full text

Abstract:

Object Microfibrillar collagen hemostat (MCH; trade name Avitene) is a partially water-insoluble acid salt of purified bovine corium collagen. This agent has been widely used to control hemorrhage at surgery, and especially during pediatric neurosurgeries at the authors' institution. Despite its effectiveness, rare case reports detailing adverse inflammatory reactions to MCH have been documented. Based primarily on MR imaging, postoperative reactions have most commonly elicited clinical differential diagnoses of tumor recurrence or abscess. According to the literature, MCH induces a very chara

APA, Harvard, Vancouver, ISO, and other styles

22

Anton, Corina-Ioana, Ion Ștefan, Simona Mihaela Dumitrache, et al. "Analysis of Aetiological Agents in Infectious Endocarditis in the Central Military Emergency University Hospital “Dr. Carol Davila” Bucharest." Microorganisms 12, no. 5 (2024): 910. http://dx.doi.org/10.3390/microorganisms12050910.

Full text

Abstract:

Background: Infective endocarditis (IE) is a pathological condition caused by various microbial agents that can lead to severe complications affecting the heart. Accurate diagnosis is crucial for the effective management of patients with IE. Blood culture is the gold standard for identifying the primary infectious agents, which is a key factor in diagnosing IE using the modified Duke criteria. Objective: The main objective of this study was to investigate the distribution of the etiological agents of IE and the most common secondary diagnoses associated with it. Method: A total of 152 patients

APA, Harvard, Vancouver, ISO, and other styles

23

Picozzi, Vincent J., Anne-Marie Duliege, Anirban Maitra, et al. "Abstract PO-050: Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC)." Cancer Research 81, no. 22_Supplement (2021): PO—050—PO—050. http://dx.doi.org/10.1158/1538-7445.panca21-po-050.

Full text

Abstract:

Abstract Background: Drug development in PDAC has been disappointing with an extremely low trial success rate despite considerable effort. PrP is a transformative, adaptive clinical trial platform that attempts to correct this by continuously and rapidly evaluating novel therapeutic options while maximizing the probability of patient (pt) randomization to an experimental treatment and nurturing enhanced cooperation among groups representing pt advocacy, pharmaceuticals, translational/clinical academia, and the FDA. This patient-centric study represents a fundamental shift in drug development f

APA, Harvard, Vancouver, ISO, and other styles

24

Yılmaz, Fatih, Havva Kaya, and Mehmet Özdemir. "Investigation of Children with Acute Gastroenteritis by Multiplex PCR Method in Central Part of Turkey." Journal of Pediatric Infectious Diseases 17, no. 01 (2022): 048–52. http://dx.doi.org/10.1055/s-0041-1740372.

Full text

Abstract:

Abstract Objective Gastroenteritis is a disease that affects all age groups, especially children, and causes high mortality and morbidity in all countries. The most common agents of acute gastroenteritis are viral agents. As a result, millions of diarrhea attacks and hospital admissions occur worldwide every year due to viral gastroenteritis. This study uses the multiplex polymerase chain reaction (PCR) method to investigate the viruses that are the causative agents of viral gastroenteritis in the pediatric patient group in Konya, Turkey. Methods Stool samples of 94 patients aged 0 to 18 years

APA, Harvard, Vancouver, ISO, and other styles

25

Kolegaeva, I. M. "IMAGES OF HUNGER, SATIATION AND THIRST IN THE MIRROR OF ENGLISH AND UKRAINIAN PHRASEOLOGY. Article 3." Writings in Romance-Germanic Philology, no. 2(49) (January 16, 2023): 28–50. http://dx.doi.org/10.18524/2307-4604.2022.2(49).268212.

Full text

Abstract:

This publication is the final, third article of the thematic cycle Images of feeding/eating food in the mirror of English and Ukrainian phraseology. It is devoted to the problem of figurative understanding and phraseological description of the processes (including causes and consequences) of CONSUMING food or drinks. The material considered by us offers the possibility of ethnocultural comparative analysis of two unrelated societies — Ukrainian-speaking and English-speaking ones. Based on A. Maslow’s thesis about the basic level of needs in the phylogenetic development of a person as a biologi

APA, Harvard, Vancouver, ISO, and other styles

26

Juergens, Rosalyn A., and Charles M. Rudin. "Aberrant Epigenetic Regulation: A Central Contributor to Lung Carcinogenesis and a New Therapeutic Target." American Society of Clinical Oncology Educational Book, no. 33 (May 2013): e295-e300. http://dx.doi.org/10.14694/edbook_am.2013.33.e295.

Full text

Abstract:

Carcinogenesis is driven by a combination of genetic and epigenetic abnormalities. Aberrancies in gene promoter methylation patterns and histone acetylation are associated with silencing of tumor suppressor genes in lung cancer and other solid tumors. Identification of key epigenetic modifications has been shown to be prognostic in early-stage non-small cell lung cancer. Previous clinical trials aimed at modifying the epigenome with single-agent demethylating agents or histone deacetylase inhibitors given at maximally tolerated doses have provided disappointing results. A recent clinical trial

APA, Harvard, Vancouver, ISO, and other styles

27

De Wit, Krista. "Person-centred Music-making as a Cultural Change Agent for Compassionate Healthcare." Research in Arts and Education 2021, no. 4 (2021): 326–54. http://dx.doi.org/10.54916/rae.119540.

Full text

Abstract:

To meet the care needs of the rapidly ageing patient populations, the cultivation of a compassionate patient-centred healthcare culture has becomecentral in the value-based healthcare discourse. A participatory music practice, ‘Meaningful Music in Healthcare’ employs a person-centred approach tomusic-making in Dutch hospitals. A grounded theory analysis on ethnographically collected data suggests that music-making serves as a social change agent and cultural resource for catalysing compassionate contact between healthcare professionals and patients. Processes of experiential growth and shared

APA, Harvard, Vancouver, ISO, and other styles

28

Darling, Julianne O., Farah Raheem, Katelyn C. Carter, Elizabeth Ledbetter, Jennifer F. Lowe, and Christopher Lowe. "Evaluation of a Pharmacist Led Oral Chemotherapy Clinic: A Pilot Program in the Gastrointestinal Oncology Clinic at an Academic Medical Center." Pharmacy 8, no. 1 (2020): 46. http://dx.doi.org/10.3390/pharmacy8010046.

Full text

Abstract:

Oral chemotherapy represents a major patient-centric advancement in therapy convenience. However, ownership of safe and correct administration of these agents requires significant patient education. To address this challenge, an in-person pharmacist-led oral chemotherapy education clinic in gastrointestinal oncology patients within an academic medical center was created and assessed. In this pilot program, a medication-specific quiz was administered to patients before and after education performed by a pharmacist to assess patient understanding of their new oral chemotherapy. A five-question s

APA, Harvard, Vancouver, ISO, and other styles

29

Watters, M. P. R., and J. M. Mckenzie. "Inhalational Induction with Sevoflurane in an Adult with Severe Complex Central Airways Obstruction." Anaesthesia and Intensive Care 25, no. 6 (1997): 704–6. http://dx.doi.org/10.1177/0310057x9702500621.

Full text

Abstract:

Sevoflurane is a newly available volatile anaesthetic agent which is suitable for inhalational induction of anaesthesia. Due to concerns about obstructing the upper airway as anaesthesia deepens, its use has until now been avoided in patients with upper airway obstruction. We used its smooth induction and recovery properties however to anaesthetize a patient with central airway obstruction and coexistent ischaemic heart disease. Sevoflurane proved to be a very satisfactory agent in this situation.

APA, Harvard, Vancouver, ISO, and other styles

30

Smieško, Gordana, Marija Baroš-Brkljača, and Pavle Banović. "Increased incidence of urinary tract infections caused by Enterococcus in COVID-19 patients of the Clinical Center of Vojvodina." PONS - medicinski casopis 19, no. 1 (2022): 4–8. http://dx.doi.org/10.5937/pomc19-37033.

Full text

Abstract:

Objective. To investigate the frequency of isolates of various uropathogens in patients of the COVID-19 Hospital "Mišeluk" in comparison with patients from the nonCOVID-19 zone of the Clinical Center of Vojvodina (KCV). Methods. For the purpose of this study, information was collected on urine isolates sent from the COVID-19 hospital and the non-COVID-19 zones of the Clinical Center of Vojvodina in a three-month period, with samples from the non-COVID-19 zone KCV used as controls. Results. Of the 449 patients from the COVID-19 Hospital, the most common causative agents of intrahospital urinary

APA, Harvard, Vancouver, ISO, and other styles

31

Burlea, Lucian Stefan, Doriana Agop-Forna, Mihaela Salceanu, et al. "INTEGRATING HYPERTONIA REHABILITATION, INTRAORAL REHABILITATION, AND ANXIETY MANAGEMENT FOR COMPREHENSIVE PATIENT CARE- PART1." Romanian Journal of Oral Rehabilitation 16, no. 4 (2024): 504–11. https://doi.org/10.62610/rjor.2024.4.16.49.

Full text

Abstract:

As stomatognatic system dysfunctions, hypertonias are quite common. As premedication, miorelaxants, adjuvants for inflammatory processes (which result in antalgic hypertonic phenomena), and during local anesthesia through neuromuscular transmission blockage, miorelaxants are a class of pharmacological agents with various structures and mechanisms of action that are highly helpful in treating stomatognatic dysfunctions. The most current medication utilized for stomatognatic system miorelaxation is Botox, which has a favorable local administration impact in a variety of clinical circumstances an

APA, Harvard, Vancouver, ISO, and other styles

32

Ansell, S. M., S. M. Geyer, P. J. Kurtin, et al. "Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7532. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7532.

Full text

Abstract:

7532 Background: Mantle Cell Lymphoma (MCL) is characterized by t(11;14) resulting in over expression of cyclin D1, a member of the phosphatidylinosital 3-kinase (PI3K) pathway. Temsirolimus is a novel inhibitor of the mammalian target of rapamycin (mTOR) kinase. Previous studies with weekly temsirolimus at a dose of 250mg demonstrated a 38% overall response rate in 35 patients (JCO 23 (23); 5347–56, 2005). Thrombocytopenia was frequently observed and was dose limiting. The current study tested whether low-doses (25mg) of temsirolimus could produce a similar overall response rate (ORR) with le

APA, Harvard, Vancouver, ISO, and other styles

33

Bojić-Đurović, Milica, Miloš Bojić, Ana Popović, Mileta Golubović, and Milena Ražnatović-Đurović. "Switching biologics in psoriasis: Challenges and experience from a small tertiary health-care center." Sanamed, no. 00 (2024): 46. http://dx.doi.org/10.5937/sanamed0-48793.

Full text

Abstract:

Objective: Psoriasis, a chronic inflammatory skin disease, significantly impacts patients' quality of life. Over the last decade, therapeutic goals have aimed to complete skin clearance and restore normal patient activities, minimizing the disease's impact on social, family, and work activities. Biologics have emerged as a promising solution to achieve better disease control without organ-specific side effects, helping meet these therapeutic goals. However, it was soon noticed that approximately 30% of patients do not sufficiently react to the therapy in the long term, and the need for switchi

APA, Harvard, Vancouver, ISO, and other styles

34

Kris, Chandra, and Budi Kurniawan M. "Ultrasound Guided Brachiocephalic Vein Cannulation using Supraclavicular Approach." Journal of Health and Medical Sciences 4, no. 4 (2021): 6–10. https://doi.org/10.31014/aior.1994.04.04.187.

Full text

Abstract:

The need of central vein cannulation has been increased since the increased case of critical patients and patients underwent high-risk patients. Supraclavicular approach of central vein cannulation is an alternative approach to central vein cannulation due to fewer anatomical variance, good longitudinal vein view, better visualization of needle during procedure, clear demarcation of landmarks, larger target area, better patient comfort, and fewer complications. This case study presents an ultrasound guided central vein cannulation using supraclavicular approach in 30 year old male patient diag

APA, Harvard, Vancouver, ISO, and other styles

35

Witzig, Thomas, Susan Geyer, Irene Ghobrial, et al. "Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group." Blood 104, no. 11 (2004): 129. http://dx.doi.org/10.1182/blood.v104.11.129.129.

Full text

Abstract:

Abstract Purpose: Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1, a member of the phosphatidylinosital 3 kinase (PI3K) pathway. This study tested whether CCI-779, which inhibits the PI3K pathway at the level of the mammalian target of rapamycin (mTOR) could produce tumor responses in patients (pts) with MCL. Patients and Methods: Eligible pts had biopsy-proven, cyclin D1 positive MCL and had relapsed or were refractory to therapy. Pts received CCI-779 250 mg IV every week as a single agent. Pts were re-staged after 1 cycle (4 doses) and every

APA, Harvard, Vancouver, ISO, and other styles

36

Erramshetty, Sidharth, D. Srisakthi, Lalitha Rani Chellappa, and Meignana Arumugham Indiran. "Beyond the Surface: A Deep Dive into Use of Fluoridated vs Non-fluoridated Remineralizing Agents on Permanent Teeth: A Systematic Review." Journal of Pioneering Medical Sciences 13, no. 7 (2024): 53–59. https://doi.org/10.47310/jpms2024130710.

Full text

Abstract:

Objectives: Dental caries, characterized by white spot lesions (WSLs), impact approximately 49% of the population and can progress to irreversible damage if untreated. Fluoridated remineralizing agents have traditionally been the standard treatment due to their efficacy in surface remineralization. However, concerns over fluoride toxicity, including risks of dental and skeletal fluorosis, have spurred interest in non-fluoridated alternatives. This systematic review evaluates the remineralizing potential of fluoridated versus non-fluoridated agents for early enamel carious lesions in permanent

APA, Harvard, Vancouver, ISO, and other styles

37

Blanchard, Sierra, Suzzane Li, and Danielle Weiler. "Erdafitinib-associated Central Serous Chorioretinopathy: A Case Report." Canadian Journal of Optometry 84, no. 4 (2022): 35–40. http://dx.doi.org/10.15353/cjo.v84i4.4349.

Full text

Abstract:

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor approved to treat patients with metastatic or advanced urothelial carcinoma and is being developed for the treatment of other cancer types. This oral chemotherapeutic agent carries a warning for potential ocular adverse reactions including central serous chorioretinopathy and dry eyes. This case report describes an 88-year-old Caucasian male co-managed in the eye clinic over the course of treatment with erdafitinib for metastatic urothelial carcinoma. The patient developed asymptomatic episodes of recurring and remi

APA, Harvard, Vancouver, ISO, and other styles

38

Kebudi, Rejin, Serap Karaman, Hande Kizilocak, et al. "Central Nervous System Fungal Infections in Children with Leukemia, Risk Factors and Outcome: A Multicentric Study." Blood 132, Supplement 1 (2018): 5169. http://dx.doi.org/10.1182/blood-2018-99-112712.

Full text

Abstract:

Abstract Introduction:Invasive fungal infections, including central nervous system fungal infections (CNSFI), cause significant morbidity and mortality in children with leukemia,necessitating early diagnosis and treatment. Material and Method: In this retrospective study, the demographic features, diagnostic approach, treatment and outcome of CNSFI in 32 children with leukemia treated in 12 centers in Turkey were evaluated. Results:Of the 32 patients,12 were female,20 were male.The diagnosis was ALL in 23, recurrent ALL in 5, CML in 1, AML in 1; two others had underwent allogeneic bone marrow

APA, Harvard, Vancouver, ISO, and other styles

39

Grommes, Christian, Alessandro Pastore, Igor Gavrilovic, et al. "Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma." Blood 128, no. 22 (2016): 783. http://dx.doi.org/10.1182/blood.v128.22.783.783.

Full text

Abstract:

Abstract BACKGROUND: Primary Central Nervous System Lymphoma (PCNSL) is an aggressive primary brain tumor with median progression free survival (PFS) after upfront methotrexate-based chemotherapy of 2-3 years. Outcome and treatment options are poor for recurrent/refractory (r/r) disease. Response rates (ORR) range between 30-60% with a PFS of 2-5 months. Ibrutinib has shown promising clinical response in Mantel cell lymphoma, CLL, and Waldenström. This trial investigates Ibrutinib in patients with r/r PCNSL and SCNSL. METHODS: Eligible patients had r/r PCNSL or Secondary CNS Lymphoma (SCNSL),

APA, Harvard, Vancouver, ISO, and other styles

40

Hilley, P., C. Li Wai Suen, A. Srinivasan, M. C. Choy, and P. De Cruz. "P379 Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents." Journal of Crohn's and Colitis 15, Supplement_1 (2021): S393. http://dx.doi.org/10.1093/ecco-jcc/jjab076.503.

Full text

Abstract:

Abstract Background The availability of subcutaneous (SC) administration devices of biologics in addition to intravenous (IV) administration has influenced patients’ and clinicians’ preferences towards initiating or transitioning to SC administration particularly during the COVID-19 pandemic. Whilst SC administration improves patient convenience and reduces demands on infusion centres we hypothesised that the reduction in healthcare contact associated with SC therapies may reduce the opportunities available for objective disease assessment. We aimed to compare the uptake of objective assessmen

APA, Harvard, Vancouver, ISO, and other styles

41

ERDİN, Züleyha, Sümeyye Buse BALCI, and Gulali AKTAS. "A rare complication of central fascial paralysis associated with quinolone." Journal of Medicine and Palliative Care 4, no. 6 (2023): 718–20. http://dx.doi.org/10.47582/jompac.1398220.

Full text

Abstract:

Quinolones, which are broad-spectrum antibiotics, are frequently preferred in the treatment of infections. In infections developing in immunosuppressed patients, side effects of quinolones, which are started empirically without determining the agent and etiology, are also quite common. In this article, central facial paralysis due to ciprofloxacin initiated for anal abscess in an immunosuppressed patient receiving chemotherapy for multiple myeloma is described, and we aim to draw attention to this rare side effect. To the best of our knowledge, this is the first case reported in the literature

APA, Harvard, Vancouver, ISO, and other styles

42

Gulea, Claudia, Rosita Zakeri, and Jennifer K. Quint. "Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison." BMJ Open 8, no. 11 (2018): e024736. http://dx.doi.org/10.1136/bmjopen-2018-024736.

Full text

Abstract:

IntroductionPatients with chronic obstructive pulmonary disease (COPD) who have a clinical indication for beta-blocker therapy, are often not prescribed such medication, despite evidence suggesting that beta-blockers are not associated with adverse respiratory outcomes. The primary objective of this systematic review and meta-analysis is to examine the class effect of beta-blocker use in patients with COPD. We will focus on a broad range of endpoints including, clinical, safety, and patient-centric outcomes such as health related quality of life (HRQoL) and functional capacity. A secondary obj

APA, Harvard, Vancouver, ISO, and other styles

43

Smith, Neil R., Jean-Christophe Pignon, Scott A. Shell, Arialle Yablonovitch, Juergen Scheuenpflug, and Zheng Feng. "Abstract 5748: Longitudinal evaluation of ctDNA molecular response for monitoring clinical benefit and investigating treatment related impacts in metastatic colorectal cancer patients treated with different drug regimens." Cancer Research 82, no. 12_Supplement (2022): 5748. http://dx.doi.org/10.1158/1538-7445.am2022-5748.

Full text

Abstract:

Abstract Introduction: The patient-centric liquid biopsy approach to detect changes in ctDNA provides an early indication of treatment response to therapies and is an emerging tool to aid clinicians in treatment decision making. We investigated this approach in the mCRC palliative treatment setting by exploring the potential clinical utility of the validated Guardant Health Molecular Response (MR) algorithm. Methods: Longitudinal plasma samples (70) were collected from 14 patients with mCRC and treated using chemotherapy alone or combined with one or more targeting agents. All patients were cl

APA, Harvard, Vancouver, ISO, and other styles

44

Adjei, A. A., J. R. Molina, S. L. Hillman, et al. "A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7547. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7547.

Full text

Abstract:

7547 Background: Sorafenib is a multikinase inhibitor with single-agent activity in previously treated NSCLC. In an effort to evaluate its single agent activity in previously untreated NSCLC, the NCCTG undertook a front-line “window of opportunity” study. Materials and Methods: Patients with stage IIIB (pleural effusion) or stage IV NSCLC received sorafenib dosed at 400 mg BID continuously, with a cycle defined as 4 weeks. Patients were evaluated weekly during the first 2 cycles with those who progressed rapidly going on to receive standard chemotherapy. Based on a two-stage Fleming design, if

APA, Harvard, Vancouver, ISO, and other styles

45

Cornell, Susan A. "A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes." Journal of Clinical Pharmacy and Therapeutics 38, no. 3 (2013): 181–89. http://dx.doi.org/10.1111/jcpt.12040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Milakovic, Branko, Ivan Dimitrijevic, Vesna Malenkovic, Dejan Markovic, Vesna Pantic-Palibrk, and Ljiljana Gvozdenovic. "Preoperative assessment and preparation of patients with diseases affecting the central nervous system." Acta chirurgica Iugoslavica 58, no. 2 (2011): 83–90. http://dx.doi.org/10.2298/aci1102083m.

Full text

Abstract:

Purpose of review: This review will examine the most important issues of preoperative evaluation and preparation in relation to patients with deseases affecting the central nervous system. Those patients may undergo various forms of surgery unrelated to the central nervous system disease. We discuss the effect of physiologic and pharmacological factors on cerebral autoregulation and control of intracranial pressure alongside its clinical relevance with the help of new evidence. Recent findings: Regardless of the reason for surgery, coexisting diseases of brain often have important implications

APA, Harvard, Vancouver, ISO, and other styles

47

Shreyash, Gugliya Rinkesh Zanjari Dr. Aman Upaganlawar* Dr. Manojkumar Mahajan Dr. Chandrashekhar Upasani. "Current Advances in Pharmacotherapy for Diabetes Mellitus: A Comprehensive Review." International Journal of Scientific Research and Technology 2, no. 3 (2025): 252–61. https://doi.org/10.5281/zenodo.15038248.

Full text

Abstract:

Diabetes mellitus poses a significant global health challenge, driving the need for ongoing advancements in pharmacotherapy. This review examines recent developments in the management of diabetes, focusing on innovative therapeutic agents and emerging technologies. Notably, tirzepatide, a first-in-class medication approved by the FDA, targets both GLP-1 and GIP receptors, enhancing insulin production and improving glycemic control while also addressing weight management and cardiovascular risks. We explore the potential of gene therapy and stem cell interventions, which aim to address the unde

APA, Harvard, Vancouver, ISO, and other styles

48

Omuro, Antonio M. P., and Lauren E. Abrey. "Chemotherapy for primary central nervous system lymphoma." Neurosurgical Focus 21, no. 5 (2006): 1–8. http://dx.doi.org/10.3171/foc.2006.21.5.13.

Full text

Abstract:

✓Chemotherapy, with or without radiotherapy, is the mainstay of treatment for primary central nervous system lymphoma (PCNSL). High-dose methotrexate (MTX) is the most effective drug available to treat these lesions, and it is used in doses of 1 to 8 g/m2, either as a single agent or in combination with other drugs such as corticosteroid agents, cytarabine, procarbazine, vincristine, carmustine, lomustine, thiotepa, cyclophosphamide, temozolomide, and rituximab. To date, an overwhelming number of different regimens in which high-dose MTX is used have been reported. Given the lack of randomized

APA, Harvard, Vancouver, ISO, and other styles

49

Doyle, Chelsey, Breedge Callaghan, Anton W. Roodnat та ін. "The TGFβ Induced MicroRNAome of the Trabecular Meshwork". Cells 13, № 12 (2024): 1060. http://dx.doi.org/10.3390/cells13121060.

Full text

Abstract:

Primary open-angle glaucoma (POAG) is a progressive optic neuropathy with a complex, multifactorial aetiology. Raised intraocular pressure (IOP) is the most important clinically modifiable risk factor for POAG. All current pharmacological agents target aqueous humour dynamics to lower IOP. Newer therapeutic agents are required as some patients with POAG show a limited therapeutic response or develop ocular and systemic side effects to topical medication. Elevated IOP in POAG results from cellular and molecular changes in the trabecular meshwork driven by increased levels of transforming growth

APA, Harvard, Vancouver, ISO, and other styles

50

Faje, Alexander T., Lisa Nachtigall, Deborah Wexler, Karen K. Miller, Anne Klibanski, and Hideo Makimura. "Central Diabetes Insipidus: A Previously Unreported Side Effect of Temozolomide." Journal of Clinical Endocrinology & Metabolism 98, no. 10 (2013): 3926–31. http://dx.doi.org/10.1210/jc.2013-2435.

Full text

Abstract:

Abstract Context: Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system. We describe 2 patients with apparent TMZ-induced central diabetes insipidus. Using our institution's Research Patient Database Registry, we identified 3 additional potential cases of TMZ-induced diabetes insipidus among a group of 1545 patients treated with TMZ. Case Presentations: A 53-year-old male with an oligoastrocytoma and a 38-year-old male with an oligodendroglioma each developed symptoms of polydipsia and polyuria approximately 2 months after the initiation of TMZ.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!